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Resistance to antibiotics has become a major threat to modern
medicine. The ribosome plays a fundamental role in cell vitality by
the translation of the genetic code into proteins; hence, it is a
major target for clinically useful antibiotics. We report here the
cryo-electron microscopy structures of the ribosome of a patho-
genic aminoglycoside (AG)-resistant Pseudomonas aeruginosa
strain, as well as of a nonresistance strain isolated from a cystic
fibrosis patient. The structural studies disclosed defective ribo-
some complex formation due to a conformational change of rRNA
helix H69, an essential intersubunit bridge, and a secondary bind-
ing site of the AGs. In addition, a stable conformation of nucleo-
tides A1486 and A1487, pointing into helix h44, is created
compared to a non-AG-bound ribosome. We suggest that altering
the conformations of ribosomal protein uL6 and rRNA helix H69,
which interact with initiation-factor IF2, interferes with proper
protein synthesis initiation.
ribosome | antibiotic | resistance | aminoglycoside | cystic fibrosis
Aminoglycosides (AGs), which are frequently used for thetreatment of many Gram-negative and some Gram-positive
infections, are also routinely applied against Pseudomonas aerugi-
nosa (PA) infections in cystic fibrosis (CF) patients (1, 2). These
antibiotics bind to bacterial ribosomes and inhibit transfer RNA’s
(tRNA’s) translocation, reduce translational fidelity, modify the
ribosome subunits’ mobility, inhibit ribosome recycling (3), in-
terfere with formation of the intersubunit bridges, and conse-
quentially prevent protein synthesis (4–7). This is achieved by
primary binding to helix 44 (h44) of the 16S ribosomal RNA
(rRNA), displacing nucleotides A1492 and A1493 (A1486 and
A1487 in PA numbering) in the 30S subunit (8, 9). Additional
elements within the AG binding pocket include the universally
conserved protein uS12, G522 of h18 (G530 in Escherichia coli
numbering), and A1903 of large subunit (LSU) H69 (A1913 in E.
coli). The secondary AG binding site to helix 69 (H69) of the 23S
rRNA in the 50S subunit may also play a role in AG-mediated
protein synthesis inhibition (6, 10).
Resistance to AGs is mainly acquired by 3 mechanisms: 1) re-
duced uptake of the drugs due to decreased permeability of the
cell membrane and overexpression of efflux pumps, which actively
expel the drugs (11); 2) acquisition of AG-modifying enzymes,
encoded by mobile genetic elements, which chemically modify and
inactivate the drug (12); and 3) by 16S rRNA methyltransferases
(RMTases), which methylate specific nucleotides in the antibiotic
binding site of the 16S rRNA, preventing binding of the antibiotic
(N7-G1405 16S-RMTases and N1-A1408 16S-RMTases) (13, 14).
In general, antibiotic resistance is often caused by mutations at or
near the drug binding site (15). Therefore, antibiotic treatment of
infections is expected to result in an accumulation of mutations in
genes encoding rRNAs and ribosomal proteins (rProteins). How-
ever, such mutations are not commonly observed in clinically iso-
lated strains, and only a limited number have been identified in E.
coli and Mycobacterium tuberculosis (15–18). One explanation for
this apparent absence of such target mutations could be that mu-
tations in ribosomal genes may result in decreased within-host
fitness when the selective pressure is removed. Additionally, re-
sistance mutations in rRNA genes need to be recombined into all
copies of the chromosomal rRNA genes before full antibiotic
resistance is developed.
Recently, in a large collection of whole-genome-sequenced
clinical PA isolates from early stage lung infections in CF pa-
tients (19), we identified 2 strains infecting the same patient
(358 and 359). These 2 isolates had minimum inhibitory con-
centration (MIC) values for the AG tobramycin that were 128-
fold (358) and 8-fold (359) higher than the European Committee
on Antimicrobial Susceptibility Testing clinical breakpoint for this
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antibiotic. The values for gentamicin were 128-fold (358) and
16-fold (359) higher (MIC assessed by Etest at the clinic).
Searching for mutations potentially involved in AG resistance
in the 2 strains (358 and 359) revealed an in-frame 12-nucleo-
tide deletion (-GCTTTGTAACCA) in the rplF ribosomal gene,
encoding the uL6 protein of the 50S subunit, in both isolates,
which were not identified in any other isolate from this col-
lection. The mutation results in a GYKA deletion after amino
acid residue 92 and a resulting shorter loop of the C-terminal
domain of the uL6 rProtein, which could be the cause of the
observed phenotype.
Here, we report the structure of the ribosome from the PA
358 clinical strain harboring the 12-nucleotide deletion in the
rplF gene and the structure of the ribosome from the wild-type
iso-clonal isolate (366), carrying a nonmutated rplF. In order
to shed light on the phenotypic behavior, high-resolution cryo-
electron microscopy (cryo-EM) structures of ribosomes from
both the wild-type and the mutant ribosomes were determined
and comparatively analyzed. Based on our results, we propose
an explanation for the formation of defective ribosome com-
plex and a weak AG binder. A conformational change of H69
and a shorter uL6 loop may interfere with proper binding
of initiation factor 2 (IF2) and, hence, with proper protein
synthesis initiation.
Results
The rplF Mutation Causes a Reduction in Growth Rate and Resistance
to Gentamicin.The generation times of isolates 359 and 358 were of
1 h and 40 min on average, 2.6- ± 0.1-fold higher than those of the
native isolates (366 and 368) that only required 40 min to double
their population in our growth conditions. Since both clinical uL6
mutant strains showed a reduced growth rate and an increased AG
resistance relative to the native strains, we evaluated the effect of
the mutation on both phenotypes by complementation analysis of
the strains. Plasmid-mediated complementation of the rplF muta-
tion by expressing a wild-type copy of the rplF gene under its own
promoter showed a statistically significant increase in growth rate
(68% relative to mutant strain containing the pCE [empty] vector
plasmid; Student’s t test; P < 0.0001) (Fig. 1A) and a considerable
decrease in MIC to gentamicin (Fig. 1B), indicating a direct re-
lationship between growth rate and ribosome functionality.
Determining the gentamicin susceptibility in vitro (half-
maximal inhibitory concentration [IC50]), using a cell-free
coupled transcription–translation system, showed a 1.8- and
2.3-fold higher IC50 (1-way ANOVA followed by Tukey’s post
hoc test; P < 0.001) for the mutant strain relative to the native
strain and to PAO1 wild-type ATCC strains, respectively (Fig.
1C). These results agree with the determined MIC for gen-
tamicin of the respective clinical strains.
Fig. 1. Effect of rplFmutation on growth phenotype and gentamicin resistance. (A) Complementation assay of rplfmutation. The wild-type copy of rplF
gene was expressed from a plasmid (pCrplF ) in native and mutant strains and the generation time was assessed. The empty plasmid (pCE) was used as
control. Error bars represent the SD of 3 independent replicates. Differences between conditions were computed by using the student test (P < 0.0001).
(B) MIC for gentamicin antibiotic for the native and mutant strains containing the pCE empty plasmid, the pCrplF plasmid containing the wild-type copy
of the rplF gene, and the pCL6M plasmid containing the mutated copy of the rplF gene. (C ) Inhibition of translation as results of increasing concen-
trations of gentamicin antibiotic resulting from the translation of the firefly luciferase in vitro translation system. Note that at low gentamicin con-
centrations (1 × 10−4 to 3.6 × 10−3 μg·mL−1), the in vitro translational activity is comparable between wild-type (PAO1 and native) and mutant
ribosomes. ns, not significant differences. The values represent the mean ± SE (n = 3) of the luminescence. Differences between the IC50 values were
computed by using 1-way ANOVA followed by Tukey’s post hoc test (P < 0.01). (D) Molecular assessment of the ribosome functionality. Sedimentation
profiles (10–50% sucrose gradient) of wild-type (PAO1 and native) and rplF mutant total ribosome fraction are shown.
22276 | www.pnas.org/cgi/doi/10.1073/pnas.1909831116 Halfon et al.
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The uL6 Deletion Reduces the Fraction of Translationally Active
Ribosomes. In bacteria, the content of active ribosomes deter-
mines growth rate (20). Since the rplF mutant strains showed
reduced growth rates compared with wild-type strains, we an-
alyzed the consequences of the uL6 mutation for the structure
and function of the mutant ribosomes. Sucrose gradient anal-
ysis of the ribosomal particles from native and mutant strains
revealed that uL6 mutant ribosomes are characterized by re-
duced 70S particle fractions relative to separated 30S and 50S
free subunits (Fig. 1D). Since translational activity depends on
assembled 70S particles, the suggested in vivo instability of the
uL6 mutant ribosomes may explain the reduced growth rates of
the mutant strains.
Cryo-EM Near-Atomic Structures of Native and uL6 Mutant PA
Ribosomes. To further investigate the resistance mechanism and
growth defects of the uL6 mutated ribosomes, we employed single-
particle cryo-EM techniques. We determined and compared the
structures of intact ribosomes purified from the native (PAnat)
and the uL6 mutant (PAuL6m) clinical isolates (Fig. 2A). The
nominal map resolutions for 70S ribosomes were 3.3 and 2.9 Å
and for the 50S subunits 3.3 and 2.8 Å, respectively (SI Ap-
pendix, Figs. S1 and S2). Importantly, the resolution of the
maps extended to 2.2 Å in the core regions, enabling us to build
and refine an atomic model for both the ancestor and the
mutant (SI Appendix, Table S1).
Unique Features of the PA Ribosomes. Comparing the structure of
PAnat ribosome to other known ribosome structures revealed
certain unique PA ribosome structural features. We highlight
structural differences in rRNA H45 and H16 (Fig. 2 B and C),
where these helices are the shortest for PAnat; and rRNA H63
(Fig. 2D), where this helix is longer in PAnat and E. coli ribo-
somes. In the small subunit, 2 unique sites were identified in
rRNA helixes. In h7 (Fig. 2E), the ribosomes of the 3 pathogens
exhibited a longer helix than in Thermus thermophilus. In
B
H45
H16
H63
h7
h33
A
C D
FE
G
Fig. 2. (A) The cryo-EM structure of the PA ribosome where uL6, H69, H68, h44, h24, and paromomycin are shown as space-filling objects and are colored blue,
yellow, magenta, green, orange, and red, respectively. The PA ribosome is shown in 2 views 90° apart. (B–F) Structure comparison between PAnat, E. coli, S. aureus,
and T. thermophilus. (B) Large subunit rRNA helix H45. (C) Large subunit rRNA helix H16. (D) Large subunit rRNA helix H63. (E) Small subunit rRNA helix h7. (F)
Small subunit rRNA helix h33. PA, E. coli (PDB ID code 5NWY), S. aureus (PDB ID code 5TV7), and T. thermophilus (PDB ID code 5IMQ) are shown in orange, gray,
blue, and green, respectively. (G) The location of the rRNA helices shown in B–F is marked on the 2D map of the PA ribosome.
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contrast, h33 (Fig. 2F) of T. thermophilus is the longest and
widest helix compared to those of the 3 pathogenic ones, whereas
in E. coli and PAnat, they are the shortest. Targeting such specific
rRNA sites (Fig. 2G) may be effective against PA and mutant
strains, which are resistant to the common drugs used against PA
such as tobramycin and gentamicin.
Structural Comparison of Both PAnat and PAuL6m Mutant Ribosomes.
The comparison between the ribosome structures reveals im-
portant differences. First, wild-type rProtein uL6 shows a longer
loop in the PAnat ribosome than the mutant PAuL6m protein,
due to the deletion, which is clearly seen in the maps (Fig. 3A
and SI Appendix, Fig. S3). Second, the 2 universally conserved
nucleotides A1486 and A1487 (E. coli A1492 and A1493) in the
PAnat structure are facing outward from the AG binding site,
while in PAuL6m, the nucleotides face inward (Fig. 3B). Fur-
thermore, H69 of the PAuL6m is bent toward the large subunit
compared to the intersubunit bridge that is formed between the 2
subunits in the PAnat ribosome (Fig. 3C and SI Appendix, Fig.
S4). H69 is located in close proximity to the AG main binding
site, and its bending may diminish these interactions, which may
explain at least part of the resistance phenotype of the mutant
strain. An additional intersubunit bridge that is formed between
H68 and h24 in the PAnat ribosome structure is not visible in the
structure of PAuL6m (Fig. 3D).
Discussion
The growth defects of the PA mutant can be attributed to the
disruption of the formation of the B2a and B2b intersubunit
bridges. H69 is part of the intersubunit bridge B2a, one of
the main bridges that stabilize the 70S ribosome, connecting the
decoding and the peptidyl transferase center sites. H69 of the
PAuL6m ribosome is bent in such a way that the correct inter-
subunit bridge cannot be formed. h24 is part of the small subunit
and part of the intersubunit bridge B2b. It forms the bridge with
H68 of the large subunit. In the PAnat ribosome, the bridge
could be traced and modeled. However, h24 could not be traced
in the maps of PAuL6m, due to lack of density, which hints at the
intersubunit bridge destabilization. These findings are in ac-
cord with the sucrose-gradient determinations of the ribosomal
subunit ratio, 70S particles vs. 30S + 50S subunits, showing that
lower amounts of translationally active 70S ribosomes were
harvested from the uL6 mutant strain in comparison to ribo-
somes isolated from the PA native strain, which may explain
why the mutant bacteria grow slower than the native strain.
Moreover, H69 is located in close proximity to the AG main
binding site, and its bending diminishes the formation of a
confined binding site. In addition, the 2 universally conserved
nucleotides A1486 and A1487 (E. coli A1492 and A1493),
which face inward from h44 in PAuL6m, may lead to a weaker
AG binding, since effective binding requires their rotation.
Accurate tRNA selection by the ribosome is essential for the
synthesis of functional proteins. Previous structural studies have
indicated that the ribosome distinguishes between cognate and
near-cognate tRNAs by monitoring the geometry of the codon–
anticodon interactions of the universally conserved 16S ribo-
somal RNA bases G530, A1492, and A1493 in the decoding
center (21, 22). During decoding, nucleotides A1492 and A1493
flip out of h44, G530 moves from a syn to an anti conformation,
and each of these 3 bases interacts with the minor groove of the
codon–anticodon helix. AG binding at the upper part of h44
(main AG binding site) and subsequent displacement of A1492
and A1493 cause significant miscoding, block intersubunit rota-
tion, and inhibit translocation. The well-defined electron-density
map around these nucleotides in the PAuL6m EM map points at
their stabilized orientation within h44, which may preclude the
AG binding, since effective binding requires outward rotation of
A1486 (A1492)
A1487 (A1493)
h44
H69
A B
C D
Fig. 3. The specific differences found between the PA native and mutant ribosomes. (A) A comparison of the uL6 protein of PAnat (coral) and PAuL6m
(cyan). The red arrow marks the structural alteration of the loop due to the GYKA deletion. (B) Differences at the structure of the main AG binding site in h44
of the 16S rRNA. The red arrows indicate the flipping of the nucleotides (PA and E. coli [in brackets] numbering are used). PAnat and PAuL6m 16S rRNA are
shown in tan and blue, respectively. (C) Conformational changes of intersubunit bridge B2a: gentamycin (colored in red) is superimposed on its main binding
site at h44 and its secondary binding site at H69, from PDB ID code 4V53 (45). H69 (cyan) and h44 (blue) of PAuL6m were superimposed on PAnat helices H69
(wheat) and h44 (orange) to show the conformational changes that occur in H69 that contribute to the phenotypic characteristics of the mutant. It may also
harm the binding to the second AG binding site at H69. (D) Conformational changes at intersubunit bridge B2b: H68 (cyan) and h24 (blue) of PAuL6m were
superimposed on PAnat helices H68 (wheat) and h24 (orange) to show the flexible region of h24 that was not modeled and contribute to the phenotypic
characteristics of the mutant.
22278 | www.pnas.org/cgi/doi/10.1073/pnas.1909831116 Halfon et al.
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the 2 nucleotides. Nevertheless, it seems that both structures
reflect the known flexibility of the 2 nucleotides, which is
needed for their activity (Fig. 3B). Hence, this difference is
probably not the main reason for the lower sensitivity of the
mutant toward AG. The secondary AG binding site is in H69,
and a modification in its structure may interfere with binding of
AGs to that site (Fig. 3C).
We suggest that a distorted IF2 binding is the link between the
deletion mutation in the uL6m rProtein and the H69–h44 B2a
bridge. IF2 (Fig. 4A) is a multidomain initiation factor, which in
complex with GTP binds to fMet–tRNAfMet through its domain IV
and to the mRNA-associated 30S subunit (23), guiding major
structural rearrangements in the ribosome during initiation. Upon
GTP hydrolysis, IF2 undergoes large conformational changes,
eliminating proper interactions between IF2 and the 70S ribosome
that are required for the stabilization of the mRNA–ribosome in-
teractions during initiation. Within the 70S ribosome, IF2 interacts
on one side with uL6 via the G domain (Fig. 4B) and via its domain
IV with H69 (Fig. 4C), maintaining a close proximity to the P-site
tRNA on the other side. For illustration, we superimposed IF2 and
the P-site tRNA from PDB ID code 3JCJ (24) on both PA struc-
tures (Fig. 4A). Zooming in on both interaction sites, we examined
the consequences of the mutation in uL6 via the changes in the AG
and H69 binding sites, which may explain the instability of 70S
subunits and low protein synthesis activity of the PA mutant strain.
At the interaction site between IF2 (in red) and uL6 (Fig. 4B),
IF2 can interact with the uL6 92 loop of the PAnat and create a
similar interaction to that seen in the E. coli 70S–fMet-tRNAi
Met
–
IF2–GDPNP complex (23). Thus, a deletion in the loop of the mutant
may weaken this interaction. Importantly, sequence alignment of
the uL6 protein from 70 bacterial species, shown partially for PA,
E. coli, T. thermophilus, Bacillus subtilis, Staphylococcus aureus, and
Deinococcus radiodurans (Fig. 4D), indicates that the loop 91–96 is
100% sequence conserved in bacteria. Therefore, the effect of the
4-amino-acid deletion, along with their high conservation, may hint
at their significance for the proper ribosome function. This change
may lead to the shift of IF2 toward the uL6 loop or destabilize its
binding and displace its other end with its IV domain from H69
and initiator P-site tRNA, reaching to the AG binding site.
The overlay of the IF2 structure on the PAuL6m ribosome
suggests that H69 of the PAuL6m may clash with IF2 (Fig. 4C) or
force it to adopt a different conformation. This movement with the
lack of bridge B2a may further explain the low stability of the 70S
ribosomes in the mutant. Zooming to the tRNA–IF2–H69 inter-
action site (Fig. 4C) shows that H69 of PAuL6m does not block
the P-site tRNA binding site.
A
B C
D
Fig. 4. (A) IF2 bridges between uL6 and H69 IF2 (using PDB ID code 3JCJ) superimposed on PAnat (coral) and PAuL6m (cyan) suggests how IF2 is interacting
with both uL6 and H69. IF2 domains G, II, III, IV, and h8 are shown in red, orange, blue, purple, and green, respectively. (B) Zoom into uL6 from PAnat (coral),
PAUL6m (cyan), and E. coli (gray) interacting with the IF2 domain G (red). The shorter uL6 loop of PAuL6m (cyan) may hamper this interaction. (C) Zoom into
H69 superimposed with P-site tRNA (PDB ID code 5LMV) and with the IF2 domain IV (purple). The shift of H69 in PAuL6m mutant toward IF2 domain IV,
compared to PAnat, may lead to a clash between IF2 and H69 that may either interfere with IF2 proper binding and may hamper this function of H69. (D)
Sequence alignment of uL6 protein of PA, E. coli (EC), T. thermophilus (TT), B. subtilis (BS), S. aureus (SA), and D. radiodurans (DR). The mutation site is marked
with a red box.
Halfon et al. PNAS | October 29, 2019 | vol. 116 | no. 44 | 22279
M
ED
IC
A
L
SC
IE
N
CE
S
D
ow
nl
oa
de
d 
at
 C
O
PE
NH
AG
EN
 U
NI
VE
RS
IT
Y 
LI
BR
AR
Y 
on
 J
an
ua
ry
 1
, 2
02
0 
Interestingly, the AG binding site is located 50 Å distant from
the uL6 protein, suggesting that antibiotic resistance can also be
acquired by altering the complex structure of the ribosome, af-
fecting its interaction with central auxiliary proteins and that the
mechanistic understanding of changes in the overall ribosomal
structure may play a key role in mitigating antibiotic resistance. A
similar bacterial antibiotic-resistance mechanism, which is based
on ribosome splitting and recycling, ensuring efficient translation
even in presence of lincomycin and erythromycin, 2 antibiotics that
block protein synthesis, has been recently described (25).
Through a genetic, biochemical, and structural analysis of an
AG-resistant mutant of PA, we have shown that a deletion in the
uL6 rProtein causes a number of phenotypic changes. In addition
to resistance to members of the AG family of antibiotics, the de-
letion causes ribosomal instability and reduced growth rate. The
cryo-EM–based structural analysis of wild-type and mutant ribo-
somes has offered explanations for the changes of these pheno-
types as well as predictions for involvement of translational factors
in connection with the phenotypic consequences. This is good
news for a continued investigation of other ribosomal variant
strains obtained from antibiotic-treated CF patients (19).
Materials and Methods
Bacterial Strains and Media. PA clinical isolates were sampled and identified
from sputum samples of patient P76M4 attending the Copenhagen Cystic
Fibrosis Center at Rigshospitalet, Copenhagen (19). Analyses of the bacterial
isolates were approved by the local ethics committee of the Capital Region
of Denmark (Region Hovedstaden; registration no. H-4-2015-FSP).
For complementation purposes, rplF under its own promoter was ampli-
fied with primers EcoRI_rplF_fwd and HindIII_rplF_rev (TATAAAGCTTAT-
GACCTGGGCGTAAATGTG) from PA PAO1 and mutant clinical isolate and
cloned into EcoRI–HindIII–pSEVA332 (26) restriction sites, resulting in pCE
(empty vector), pCrplf harboring the wild-type copy of rplf gene, and pCL6M
harboring the mutant rplf gene from mutant isolate. Plasmid were trans-
ferred by triparental mating as described above using pRK2013 as helper
plasmid (27). All cloning PCRs were performed with Phusion Hot Start II
High-Fidelity DNA Polymerase (Thermo Fisher).
PCR products were purified and cloned in the pSEVA344 plasmid and
transferred to receptor strains via tripartite conjugation by using the
pRK2013 helper plasmid.
Bacterial growthwas recorded bymeasuring the turbidity at 600 nm of cell
cultures in a 250-mL flask at 250 rpm at 37 °C in Luria–Bertani (LB) medium
(28). For each strain, 3 independent biological replicates were analyzed.
Antibiotic Susceptibility Tests. MIC for gentamicin was determined in 96-well
microplates in LB medium containing decreasing concentrations (2-fold di-
lution series) of antibiotic. Plates were incubated for 48 h at 37 °C at 150 rpm.
For each strain, 3 independent biological replicates were analyzed.
PA Ribosome Purification. PA cells were grown in LB at 37 °C until mid-
exponential phase (0.6–0.8 A600), harvested at 8,000 × g for 10 min at 4 °C, and
washed twice in buffer A (50 mM Tris·HCl, pH 7.6, 10 mM MgCl2, 100 mM
NH4Cl, 0.5 mM EDTA, pH 8, and 6 mM β-mercaptoethanol). Cellular lysis was
carried out as reported (23) in buffer A containing 10 mg/mL lysozyme by
freeze–thaw in liquid nitrogen. The lysate was centrifuged at 22,000 rpm for
30 min at 2 °C, and the supernatant was stored at −80 °C. Cell extracts were
layered on a 1.1 M sucrose cushion (10 mM Hepes, pH 8.0, 14 mM MgCl2,
100 mM NH4Cl, 50 mM KCl, and 6 mM β-mercaptoethanol) and ultra-
centrifuged at 55,000 rpm using a Ti-70 rotor at 4 °C for 17 h. The supernatant
was then discarded, and the pellet was dissolved in 50 mM KCl, 14 mMMgCl2,
10 mM Hepes (pH 7.6), 100 mM NH4Cl, and 6 mM β-mercaptoethanol buffer
(pH 8.0) at 4 °C. The 70S ribosomes were purified by sucrose gradient ultra-
centrifugation, using a SW-28 rotor with a gradient of 10–50% sucrose, at high
Mg2+ concentration (14 mMMgCl2) for 17.5 h at 18,000 rpm. After separation,
the Mg2+concentration was adjusted to 10 mM, and the ribosomes were
concentrated by using centrifugation at 32,000 × g for 19 h at 4 °C and then
further concentrated at 45,000 × g for 1.5 h at 4 °C. The samples were kept in
15 mM KCl, 10 mMMgCl2, 10 mM Hepes (pH 7.6), and 60 mM NH4Cl at pH 7.6,
brought to a final concentration not exceeding 1,000 A260·mL
−1, and then
flash-frozen for storage at −80 °C.
In Vitro Inhibition of Translation Assay. The inhibition effect of gentamicin and
chloramphenicol on PA ribosomes was tested in a bacterial coupled tran-
scription/translation assay system,where the activity of the firefly luciferase was
used as a reporter (29) The luciferase gene was present on a plasmid with T7
RNA polymerase promoter. The inhibition assay, similar to what has been
described in ref. 30, was performed in solution containing 160 mMHepes–KOH
(pH 7.5); 6.5% polyethylene glycol 8 K; 0.074 mg/mL tyrosine; 1.3 mM ATP;
0.86 mM CTP, GTP, and UTP; 208 mM potassium glutamate; 83 mM creatine
phosphate; 28 mM NH4OAc; 0.663 mM cyclic adenosine monophosphate,
1.8 mM dithiothreitol, 0.036 mg/mL folinic acid, 0.174 mg/mL E. coli tRNA mix,
1 mM amino acid, 8 μMMg(OAc)2, 0.25 mg/mL creatine kinase, 0.027 mg/mL T7
RNA polymerase, 0.003 μg/μL luciferase plasmid, and E. coli S100 lysate (which
doesn’t include ribosomes) and added 300 nM ribosomes. A concentration
range of gentamicin was 2.3 mg/mL to 0.01 ng/mL in 1:2 serial dilutions. The
results were plotted, and IC50 values were calculated by using the program
GraFit (Version 7). IC50 values were determined by fitting the inhibition data to
a 4-parameter IC50 equation:
range
1+ ð xIC50Þs where range is the maximum y range, and
s is a slope factor. The x axis represents the concentration of the analyte. Data
fitted to this equation are usually displayed with a logarithmically scaled x axis.
The visualization of the data were obtained by using GraFit software (31).
Cryo-EM Data Acquisition. Similar to what was described in ref. 32, a volume
of 3.5 μL of ribosome samples was applied on glow-discharged holey carbon
grids (Quantifoil R1.2/1.3, 200 mesh) on pure ice. The grids were blotted and
plunge-frozen by using a Vitrobot Mark IV (FEI Company). Cryo-EM micro-
graphs were recorded at liquid nitrogen temperature on a Titan Krios elec-
tron microscope (FEI) operating at 300 kV. Micrographs of PAnat were recorded
on a Falcon 2 (FEI) at a magnification of 127,000, pixel size of 1.1 Å·px−1,
defocus range of 0.5–2.1 μm, and total dose of 42 e/Å2. This dataset was
collected at Monash University, Clayton, Australia.
Micrographs of PAuL6m were recorded on a Falcon 3 (FEI) at a magnifi-
cation of 127,000, pixel size of 1.1 Å·px−1, defocus range of 0.5–1.5 μm and
total dose of 40 e/Å2. This dataset was collected at the Netherlands Centre
for Electron Nanoscopy (NeCEN; Leiden, The Netherlands).
Cryo-EM Image Processing and 3D Reconstructions. Cryo-EM images were
subjected to motion correction by using MotionCor2 (33). Contrast transfer
function parameters for each micrograph were determined by CTFFIND4
(34). Particle selection, 2D and 3D classifications were performed in RELION
(Version 2.1) (35). The resulting particle projections were subjected to fur-
ther refinement with alignment focusing on the small subunit (SSU) and LSU,
respectively. Reported resolutions are based on the gold-standard Fourier
shell correlation using the 0.143 criteria (SI Appendix, Figs. S1 and S2). Local
resolution was determined by using ResMap (36) with half-reconstructions as
input maps (SI Appendix, Figs. S1 and S2).
Model Building and Refinement.Model building of the ribosomal LSU and SSU
was performed by fitting the reported model of the ribosome from T. ther-
mophilus (PDB ID code 4LF4) to the calculated density map using Chimera
(37). The docked model was manually manipulated by using COOT (38) real-
space and geometry-restraint commands to fit into the density maps. De novo
sequence-guided model building was applied to additional features that
were better resolved in the current maps. The rRNA and protein sequences
used for modeling were extracted from the PA whole-genome sequence.
Model refinement was performed by a combination of PHENIX (39) and
COOT as described (40). Structure validation was done by using Molprobity
(41). Model overfitting was evaluated through its refinement against cryo-EM
half maps (SI Appendix, Fig. S2). Figures were created by using the UCSF
Chimera package (37). Local resolution plots were generated in ResMap (36).
Figure Generation and Sequence Alignment. All figures were generated with
Chimera and ChimeraX (37, 42). uL6 multiple-sequence alignment was per-
formed by ClustalW (43) and presented by Jalview (44).
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